We are live on ! Find out more
MRNA icon

Moderna

884 hedge funds and large institutions have $26.1B invested in Moderna in 2023 Q4 according to their latest regulatory filings, with 140 funds opening new positions, 271 increasing their positions, 339 reducing their positions, and 133 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more call options, than puts

Call options by funds: $1.91B | Put options by funds: $1.43B

3.76% more ownership

Funds ownership: 64.85%68.61% (+3.8%)

5% more first-time investments, than exits

New positions opened: 140 | Existing positions closed: 133

2% more capital invested

Capital invested by funds: $25.6B → $26.1B (+$538M)

1% less funds holding

Funds holding: 889884 (-5)

15% less funds holding in top 10

Funds holding in top 10: 1311 (-2)

20% less repeat investments, than reductions

Existing positions increased: 271 | Existing positions reduced: 339

Holders
884
Holders Change
-5
Holders Change %
-0.56%
% of All Funds
12.89%
Holding in Top 10
11
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-15.38%
% of All Funds
0.16%
New
140
Increased
271
Reduced
339
Closed
133
Calls
$1.91B
Puts
$1.43B
Net Calls
+$481M
Net Calls Change
+$299M

MRNA Hedge Fund Activity: Q4 2023 in Review

884 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q4 2023, worth a combined $26.1B — up 2.1% from $25.6B a quarter earlier.

Buyers outnumbered sellers: 140 funds opened new MRNA positions and 133 closed out — a net gain of 7 holders — while 271 added to existing stakes and 339 trimmed.

The largest buyer was Vanguard Group, adding an estimated $526M. The largest seller was Coatue Management, cutting an estimated $138M.

  • 884 institutional investors held Moderna (MRNA) as of Q4 2023, down from 889 in Q3 2023.
  • Funds reported $26.1B of Moderna stock for Q4 2023, up 2.1% quarter-over-quarter.
  • 140 funds opened new Moderna positions in Q4 2023 and 133 closed out, a net change of +7 holders.
  • The largest Moderna buyer in Q4 2023 was Vanguard Group, an estimated $526M added.
  • The largest Moderna seller in Q4 2023 was Coatue Management, an estimated $138M sold.

Based on aggregated 13F filings for Q4 2023.